arrow
E

Etienne Giroux-Leprieur

hôpital marie lannelongue
H指数:30
被引数:2,930

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)

可溶性PD-L1(sPD-L1)作为接受一线免疫检查点抑制剂(ICIs)治疗的晚期非小细胞肺癌(NSCLC)患者中持久应答和生存的生物标志物

2025-08-260
OAAI
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer

FDG PET代谢参数在不可手术的III期非小细胞肺癌患者接受42 Gy放化疗前后的预后价值

2025-02-270
PRE
Role of the HGF/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer

HGF/c-MET通路在晚期非小细胞肺癌对免疫检查点抑制剂耐药中的作用

2025-01-030
OA
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice
2024-08-012
PRE
Bevacizumab in addition to standard of care did not shorten the time to improve hypoxemia in severe hypoxemic COVID-19 pneumonia in a prospective randomized controlled trial.
2023-10-270
PRE
Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy ofradiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 e IFCT 1401): A prospective multicentre, open-label, randomised, controlled trial
2023-10-011
OA
Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study
2023-01-2025
OAAI
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study

EGFR突变的晚期非小细胞肺癌对一线奥希替尼的组织分子耐药机制: 一项多中心法国回顾性研究

2022-09-2114
PRE